StockData

Vivos Inc (RDGL) stock analysis

RDGLOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 9/30
$0.05−0.00 (-2.51%)

Close on Oct 19, 2026Market cap $23.44MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth3Performance1Health5Dividend0

Mixed9 of 30 checks passed

Vivos passes 9 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
3/6
Past performance
1/6
Financial health
5/6
Dividend
0/6

What stands out

  • No debt

    Vivos has no borrowings on its latest balance sheet.

  • Revenue growing 10%+ a year

    Revenue grew 23.3% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Return on equity under 15%

    Return on equity was -133% over the last twelve months and averaged -203% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -1019%, below the 10% that usually covers the cost of capital.

  • Return on equity below the industry

    Vivos's return on equity of -133% is below the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

  • Net margin below the industry

    Vivos's net margin of -3634% is below the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth3/6

  • Revenue growing 10%+ a year

    Revenue grew 23.3% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 91.5% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was -25.9% over the last twelve months, against -92.8% a year earlier.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -133% over the last twelve months and averaged -203% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -1019%, below the 10% that usually covers the cost of capital.

  • Return on equity below the industry

    Vivos's return on equity of -133% is below the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -3634% over the last twelve months, against a 5-year average of -10694%.

  • Net margin below the industry

    Vivos's net margin of -3634% is below the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health5/6

  • No debt

    Vivos has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 48.85 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Vivos has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Vivos. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 17.1
  • Surgical, Medical, and Dental Instruments and Supplies median 3.2

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

-87.4%−107.3 pts over 5 years

Operating margin

-4628.7%+4978.8 pts over 5 years

Net margin

-4483.9%+9187.5 pts over 5 years

See a number that looks wrong?